PARIS, March 25 /PRNewswire-FirstCall/ -- Hello,
The investor meeting relating to the 2008 earnings and 2009 outlook has been webcasted. The presentation is available in English from the following link:
http://www.thomson-webcast.net/uk/dispatching/?event_id=2ef87b3007af7a71
a2e0f120f7f05e9c&portal_id=55a3fb63ef049550bc3b4d09baf7bf5e
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser’s URL address field. Remove the space if one exists.)
ABOUT STALLERGENES
Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 21% (gross) of its sales to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.
In 2008, Stallergenes had sales of EUR 171 million and provided desensitization treatments to more than 500,000 patients.
Additional financial information is available at http://www.stallergenes.com
CONTACT: Lucile de FRAGUIER, PAVIE FINANCE, T : +33(0)1-42-15-04-39,
mailto:contact@pavie-finance.com
